 |  | |
|
Investors FAQ
When was Antigenics ’ initial public offering (IPO), and what was the price?Antigenics went public at a price of $18 per share on February 5, 2000, under the symbol AGEN on the NASDAQ stock market. For information on other key company events, see Antigenics history. Has the company raised money since the IPO?The company raised net proceeds of approximately $56 million in a follow-on offering in January 2002 and net proceeds of approximately $60 million in a subsequent follow-on offering in January 2003. In September 2003, Antigenics raised $31.6 million in a private placement of Series A Convertible Preferred shares. In February 2004, Antigenics raised net proceeds of more than $50 million in a follow-on offering. In January 2005, the company completed a private placement of convertible senior notes due 2025 to third-party investors, raising net proceeds of approximately $48 million. Where are Antigenics ’ corporate headquarters?The corporate offices are located in New York City. All correspondence can be sent to the following address: 630 Fifth Avenue, Suite 2100 When are Antigenics ’ fiscal quarter and year-end dates, and what are the corresponding earnings and release dates?Antigenics is on a January-December fiscal year. That means that the company ’s quarters close on the last business date of March, June, September and December. We expect to report our earnings as follows: 1Q — Last week of April When is the next annual meeting of shareholders?The 2006 Annual Shareholders’ Meeting is Wednesday, June 14, 2006, at 5:00 p.m. ET. The 2005 Annual Shareholders’ Meeting took place on Wednesday, June 1, 2005. [audio replay] Who is Antigenics ’ transfer agent?American Stock Transfer Company I ’ve lost my stock certificates. How can I replace them?Contact Antigenics ’ transfer agent, American Stock Transfer & Trust. They can look up your records and make any necessary adjustment. There is a fee involved for replacing lost certificates. Can I purchase shares directly from the company?No, Antigenics does not have a direct stock purchase plan. Shares may be purchased through a broker of your choice. Does Antigenics pay a cash dividend?No, Antigenics does not pay an annual dividend to its shareholders. Does Antigenics have a DRIP (Dividend Reinvestment Program)?No, Antigenics does not have a Dividend Reimbursement Plan or a Direct Stock Purchase Program. Does Antigenics anticipate paying a dividend or initiating a Direct Stock Purchase Program?No, Antigenics does not anticipate paying a dividend or initiating a Direct Stock Purchase Program in the foreseeable future. How can I obtain a copy of Antigenics ’ most recent annual report?Please contact our Investor Relations department or simply download the PDF of our annual report. Can I buy options on Antigenics stock?Options on Antigenics stock are available on the American Stock Exchange. Who are the members of the Board of Directors and executive management? Who is on the Medical Advisory and Scientific Advisory Boards?For more information about leadership at Antigenics, please see the Leadership page. What are the company ’s operating expenses?Operating expenses for fiscal year 2005 were approximately $74.5 million. How much cash does the company have?On December 31, 2005, Antigenics had $61.7 million in cash. How many shares are outstanding?On December 31, 2005, there were approximately 45.6 million shares of Antigenics stock outstanding. How many options have been granted to employees and others?As of December 31, 2005, there are 4,770,605 options outstanding that have been granted to employees and directors and 1,234,131 that have been granted to others. When will Antigenics file its 10-Qs?Antigenics expects to file its 10-K and 10-Qs with the SEC based on the following schedule: 1Q — Second week of May I have Antigenics contingent value rights. What can I do with them?In July 2000, Antigenics acquired Aronex Pharmaceuticals, Inc. In addition to 0.0594 shares of Antigenics stock, each shareholder of Aronex Pharmaceuticals received one contingent value right for each share of Aronex Pharmaceuticals they owned. The rights entitled the holders fractional shares of Antigenics stock upon final approval from the US Food and Drug Administration for ATRAGEN™ (now ATRA-IV) for treatment of a certain type of leukemia by July 6, 2002. After meeting with the FDA, Antigenics made the decision not to file for leukemia. The contingent value rights expired on July 6, 2002 with no value. Please consult your tax advisor for advice on figuring the cost basis for these Antigenics shares. Antigenics intends to pursue ATRA-IV for other indications. |